ra-BEP-ra-zole
BEERS REMS
Absorption: Delayed-release tablet is designed to allow rabeprazole, which is not stable in gastric acid, to pass through the stomach intact. Subsequently 52% is absorbed after oral administration.
Distribution: Unknown.
Protein Binding: 96.3%.
Half-Life: 1–2 hr.
(acid suppression)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | within 1 hr | unknown | 24 hr‡ |
‡Suppression continues to increase over the first wk of therapy.
Contraindicated in:
Use Cautiously in:
Derm: ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS (AGEP), cutaneous lupus erythematosus, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), photosensitivity, rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN)
F and E: hypocalcemia (especially if treatment duration ≥3 mo), hypokalemia (especially if treatment duration ≥3 mo), hypomagnesemia (especially if treatment duration ≥3 mo)
GI: abdominal pain, CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), constipation, diarrhea, fundic gland polyps, nausea
GU: acute tubulointerstitial nephritis
MS: bone fracture, neck pain
Neuro: dizziness, headache, malaise
Misc: chills, fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS, ANGIOEDEMA, OR TUBULOINTERSTITIAL NEPHRITIS), systemic lupus erythematosus, vitamin B12 deficiency
Drug-drug:
Gastroesophageal Reflux Disease
Duodenal Ulcers
H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence (Triple Therapy)
Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome
Lab Test Considerations:
Do not confuse rabeprazole with aripiprazole. Do not confuse Aciphex with Accupril or Aricept.
NDC Code